India Pharma Outlook Team | Thursday, 20 November 2025
GSK plc and LTZ Therapeutics (LTZ), a biotechnology firm specializing in immunotherapy located in Redwood City, California, revealed a strategic research partnership aimed at enhancing the creation of innovative myeloid cell engagers (MCEs) to meet substantial unmet requirements in oncology.
The collaborative research seeks to create as many as four potential groundbreaking MCE treatments aimed at hematologic cancers and solid tumors. The agreement provides GSK with an exclusive opportunity to license global development and commercial rights for these pre-clinical treatments.
MCEs represent a new category of immuno-oncology therapies aimed at harnessing the body’s immune system to identify and eliminate tumor cells, offering a fresh method for targeting cancers with an advantageous safety profile.
Also Read: Pfizer & PRASHO Drive Migraine Awareness Across Hyderabad Offices
Myeloid cells constitute a large portion of the immune cells residing in tissues, offering the potential for extensive and lasting infiltration of tumors when leveraged to attack and eliminate cancerous cells. The LTZ MCE platform has demonstrated encouraging pre-clinical results regarding targeted anti-cancer effects across various tumour types.
Although other modalities have demonstrated effectiveness, they can lead to considerable side effects that necessitate inpatient monitoring, restricting their use in the community where the majority of patients obtain care
Hesham Abdullah, senior vice president, global head oncology, R&D, GSK said: “This collaboration builds on GSK’s targeted investment in next-generation technologies to advance cancer medications with transformative potential.
By combining our scientific expertise with LTZ’s innovative immune-engager platform, we aim to accelerate first-in-class myeloid cell engager therapies in haematologic cancers and solid tumours to transform outcomes with a safety profile to enable broad community access for people living with cancer.”
